NASDAQ:CTSO Cytosorbents (CTSO) Stock Price, News & Analysis → Exposed: 10 CENT Crypto to Explode April 20th? (From True Market Insiders) (Ad) Free CTSO Stock Alerts $0.82 +0.01 (+1.24%) (As of 04/26/2024 ET) Add Compare Share Share Today's Range$0.80▼$0.8250-Day Range$0.79▼$1.0452-Week Range$0.78▼$4.29Volume96,004 shsAverage Volume154,414 shsMarket Capitalization$44.48 millionP/E RatioN/ADividend YieldN/APrice Target$2.50 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Cytosorbents alerts: Email Address Cytosorbents MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.50 Rating ScoreUpside/Downside205.3% Upside$2.50 Price TargetShort InterestBearish2.85% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.00Based on 2 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.36) to ($0.17) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.0.67 out of 5 starsMedical Sector853rd out of 913 stocksSurgical & Medical Instruments Industry88th out of 95 stocks 3.3 Analyst's Opinion Consensus RatingCytosorbents has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 1 buy rating, 1 hold rating, and no sell ratings.Amount of Analyst CoverageCytosorbents has only been the subject of 1 research reports in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted2.85% of the outstanding shares of Cytosorbents have been sold short.Short Interest Ratio / Days to CoverCytosorbents has a short interest ratio ("days to cover") of 14.8, which indicates bearish sentiment.Change versus previous monthShort interest in Cytosorbents has recently decreased by 4.32%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldCytosorbents does not currently pay a dividend.Dividend GrowthCytosorbents does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for CTSO. Previous Next 0.0 News and Social Media Coverage News Coverage This WeekMarketBeat has tracked 2 news articles for Cytosorbents this week, compared to 1 article on an average week.Search InterestOnly 3 people have searched for CTSO on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Cytosorbents insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 8.10% of the stock of Cytosorbents is held by insiders.Percentage Held by InstitutionsOnly 32.87% of the stock of Cytosorbents is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Cytosorbents are expected to grow in the coming year, from ($0.36) to ($0.17) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Cytosorbents is -1.28, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Cytosorbents is -1.28, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCytosorbents has a P/B Ratio of 1.58. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Behind the MarketsBetter than Bitcoin? The Biotech Stock with 46,751% Potential4x Better than Bitcoin Bitcoin would have to go from $68,000 to $314,000 to match the 463% gains we saw with Immunogen in December.Get the name of the stock here >>> About Cytosorbents Stock (NASDAQ:CTSO)Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals. The company also develops CytoSorb-XL, a device for adjunctive therapy in the treatment of sepsis and other critical illnesses; HemoDefend blood purification technology platform to reduce contaminants in the blood supply that can cause transfusion reactions or disease when administering blood and blood products to patients, and removal of anti-A and anti-B blood group antibodies from whole blood and plasma; K+ontrol for treatment of severe hyperkalemia in patients with life-threatening conditions; and ContrastSorb for the removal of IV contrast in blood administered during CT imaging, an angiogram, or during a vascular interventional radiology procedure to reduce the risk of contrast-induced nephropathy. In addition, it develops BetaSorb, a device for the prevention and treatment of health complications caused by the accumulation of metabolic toxins in patients with chronic renal failure; DrugSorb, a device to remove drugs and chemicals from the blood; and DrugSorb-ATR, an antithrombotic removal system. The company was formerly known as MedaSorb Technologies Corporation and changed its name to Cytosorbents Corporation in May 2010. Cytosorbents Corporation was founded in 1997 and is headquartered in Princeton, New Jersey.Read More CTSO Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CTSO Stock News HeadlinesApril 26, 2024 | globenewswire.comCytoSorbents to Report First Quarter 2024 Operating and Financial ResultsApril 24, 2024 | americanbankingnews.comCytosorbents (NASDAQ:CTSO) Receives New Coverage from Analysts at StockNews.comApril 27, 2024 | Banyan Hill Publishing (Ad)Forget AI, Imperium Is Expected to Grow 320,00% in 3 YearsIf you think AI is big, then you have got to check out something I call Imperium… By my calculations, it’s set to grow 320,000% in three years. (You can see my calculations here.)April 17, 2024 | finance.yahoo.comSTAR-T Pivotal Trial Results to Be Featured as a Late-Breaking Presentation at the 2024 American Association for Thoracic Surgery Annual MeetingApril 4, 2024 | finance.yahoo.comCTSO: CytoSorbents Expects Significant Gross Margin Expansion in 2024.April 4, 2024 | finance.yahoo.comCTSO: CytoSorbents Expects Significant Gross Margin Expansion in 2023.March 16, 2024 | finance.yahoo.comCytosorbents Full Year 2023 Earnings: Misses ExpectationsMarch 16, 2024 | finance.yahoo.comCTSO Apr 2024 2.500 callApril 27, 2024 | Banyan Hill Publishing (Ad)Forget AI, Imperium Is Expected to Grow 320,00% in 3 YearsIf you think AI is big, then you have got to check out something I call Imperium… By my calculations, it’s set to grow 320,000% in three years. (You can see my calculations here.)March 15, 2024 | finance.yahoo.comQ4 2023 Cytosorbents Corp Earnings CallMarch 15, 2024 | finance.yahoo.comCytosorbents Corporation (NASDAQ:CTSO) Q4 2023 Earnings Call TranscriptMarch 14, 2024 | benzinga.comRecap: CytoSorbents Q4 EarningsMarch 14, 2024 | globenewswire.comCytoSorbents Reports Fourth Quarter and Full Year 2023 ResultsMarch 13, 2024 | markets.businessinsider.comCytosorbents earnings preview: what to expectMarch 6, 2024 | globenewswire.comCytoSorbents to Report Fiscal 2023 Operating and Financial ResultsMarch 4, 2024 | finance.yahoo.comCTSO Mar 2024 2.500 callFebruary 27, 2024 | money.usnews.comCytosorbents CorpFebruary 23, 2024 | finance.yahoo.comCytosorbents (NASDAQ:CTSO) investors are sitting on a loss of 90% if they invested three years agoFebruary 22, 2024 | benzinga.comCytoSorbents Stock (NASDAQ:CTSO) Insider TradesFebruary 22, 2024 | benzinga.comCytoSorbents Stock (NASDAQ:CTSO) Dividends: History, Yield and DatesFebruary 8, 2024 | finance.yahoo.comCytoSorbents to Present at the TD Cowen 44th Annual Health Care ConferenceJanuary 17, 2024 | finance.yahoo.comCTSO: CytoSorbents reports update on data results from important U.S. and Canadian STAR-T pivotal trial.January 17, 2024 | finance.yahoo.comGroundbreaking Randomized Controlled Trial Reports Excellent Clinical Outcomes Using CytoSorb® Intraoperatively in Heart Transplant PatientsJanuary 6, 2024 | stockhouse.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Cytosorbents Corporation - CTSODecember 30, 2023 | msn.comHC Wainwright & Co. Downgrades Cytosorbents (CTSO)December 30, 2023 | markets.businessinsider.comCytoSorbents Holds Steady with Neutral Rating Amid Clinical and Financial ReassessmentsDecember 29, 2023 | realmoney.thestreet.comCytoSorbents just downgraded at H.C. Wainwright, here's whySee More Headlines Receive CTSO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Cytosorbents and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/14/2024Today4/26/2024Next Earnings (Estimated)5/07/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Surgical & medical instruments Sub-IndustryN/A Current SymbolNASDAQ:CTSO CUSIPN/A CIK1175151 Webwww.cytosorbents.com Phone(732) 329-8885Fax732-329-8650Employees186Year FoundedN/APrice Target and Rating Average Stock Price Target$2.50 High Stock Price Target$4.00 Low Stock Price Target$1.00 Potential Upside/Downside+205.3%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($0.64) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-28,510,000.00 Net Margins-78.43% Pretax Margin-80.67% Return on Equity-120.24% Return on Assets-54.11% Debt Debt-to-Equity Ratio0.11 Current Ratio1.77 Quick Ratio1.51 Sales & Book Value Annual Sales$36.35 million Price / Sales1.22 Cash FlowN/A Price / Cash FlowN/A Book Value$0.52 per share Price / Book1.58Miscellaneous Outstanding Shares54,310,000Free Float49,907,000Market Cap$44.48 million OptionableOptionable Beta0.58 The Best High-Yield Dividend Stocks for 2024Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.Get This Free Report Key ExecutivesDr. Phillip P. Chan M.D. (Age 54)Ph.D., CEO & Director Comp: $541.93kMr. Vincent J. Capponi M.S. (Age 66)President & COO Comp: $452.62kMs. Kathleen P. Bloch CPA (Age 69)M.B.A., Chief Financial Officer Comp: $395.43kDr. Efthymios N. Deliargyris FACC (Age 56)FESC, FSCAI, M.D., Chief Medical Officer Comp: $463.15kMs. Terri Anne Powers M.B.A.Vice President of Investor Relations & Corporate CommunicationsDr. Christian Steiner M.D.Executive Vice President of Sales & MarketingMr. Christopher Cramer M.B.A.M.S., Senior Vice President of Business DevelopmentDr. Irina B. Kulinets Ph.D. (Age 69)Senior Vice President of Global Regulatory Affairs Jodi HooverExecutiveDr. Robert H. Bartlett M.D. (Age 85)Co-Chairman of Cardiac Surgery Advisory Board & Consultant Comp: $54kMore ExecutivesKey CompetitorsDaxorNASDAQ:DXRInspireMDNYSE:NSPRApyx MedicalNASDAQ:APYXHealth Sciences Acquisitions Co. 2NASDAQ:HSAQBeyond AirNASDAQ:XAIRView All CompetitorsInsiders & InstitutionsKey Client Fiduciary Advisors LLCBought 22,557 shares on 4/15/2024Ownership: 0.064%Avenir CorpBought 334,005 shares on 2/14/2024Ownership: 6.866%Neuberger Berman Group LLCBought 299,103 shares on 2/14/2024Ownership: 4.054%Neuberger Berman Group LLCBought 299,103 shares on 2/9/2024Ownership: 4.054%Sargent Investment Group LLCBought 51,699 shares on 2/5/2024Ownership: 2.945%View All Insider TransactionsView All Institutional Transactions CTSO Stock Analysis - Frequently Asked Questions Should I buy or sell Cytosorbents stock right now? 2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Cytosorbents in the last twelve months. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" CTSO shares. View CTSO analyst ratings or view top-rated stocks. What is Cytosorbents' stock price target for 2024? 2 equities research analysts have issued 1 year target prices for Cytosorbents' shares. Their CTSO share price targets range from $1.00 to $4.00. On average, they expect the company's stock price to reach $2.50 in the next twelve months. This suggests a possible upside of 205.3% from the stock's current price. View analysts price targets for CTSO or view top-rated stocks among Wall Street analysts. How have CTSO shares performed in 2024? Cytosorbents' stock was trading at $1.11 at the beginning of the year. Since then, CTSO stock has decreased by 26.2% and is now trading at $0.8190. View the best growth stocks for 2024 here. When is Cytosorbents' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 7th 2024. View our CTSO earnings forecast. How were Cytosorbents' earnings last quarter? Cytosorbents Co. (NASDAQ:CTSO) announced its quarterly earnings data on Thursday, March, 14th. The medical research company reported ($0.12) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.14) by $0.02. The medical research company had revenue of $8.67 million for the quarter, compared to analysts' expectations of $9.29 million. Cytosorbents had a negative trailing twelve-month return on equity of 120.24% and a negative net margin of 78.43%. What is Phillip Chan's approval rating as Cytosorbents' CEO? 11 employees have rated Cytosorbents Chief Executive Officer Phillip Chan on Glassdoor.com. Phillip Chan has an approval rating of 26% among the company's employees. This puts Phillip Chan in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies. 74.0% of employees surveyed would recommend working at Cytosorbents to a friend. What other stocks do shareholders of Cytosorbents own? Based on aggregate information from My MarketBeat watchlists, some companies that other Cytosorbents investors own include Rekor Systems (REKR), Advanced Micro Devices (AMD), Micron Technology (MU), Gilead Sciences (GILD), Pfizer (PFE), AbbVie (ABBV), Inovio Pharmaceuticals (INO), OPKO Health (OPK) and Sorrento Therapeutics (SRNE). Who are Cytosorbents' major shareholders? Cytosorbents' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Key Client Fiduciary Advisors LLC (0.06%). Insiders that own company stock include Al Kraus, Alan D Sobel, Edward Raymond Jones, Jiny Kim, Kathleen P Bloch, Michael G Bator, Phillip P Chan and Vincent Capponi. View institutional ownership trends. How do I buy shares of Cytosorbents? Shares of CTSO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:CTSO) was last updated on 4/27/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThese AI trades triggered this morning (545% return)Prosper Trading AcademyHe Is Giving Away BitcoinCrypto Swap ProfitsThe A.I. story nobody is telling you (Read ASAP)TradeSmithFed launches fourth dollar overhaulStansberry ResearchBiden out June 13; Kamala won’t replace him?Paradigm PressMan Who Predicted 2008: “This Will be Worse.”AltimetryExposed: 10 CENT Crypto to Explode April 20th?True Market Insiders Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cytosorbents Co. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.